All Stories

  1. Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subdermal implant
  2. Axonal self-sorting without target guidance in Drosophila visual map formation
  3. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
  4. SARS-CoV-2 Evolution on a Dynamic Immune Landscape
  5. T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
  6. Sequencing accuracy and systematic errors in nanopore direct RNA sequencing
  7. Leveraging Secondary Data for Global Health Digitalization
  8. Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021
  9. Short- and long-range interactions in the HIV-1 5′ UTR regulate genome dimerization and packaging
  10. Investigation of a Limited but Explosive COVID-19 Outbreak in a German Secondary School
  11. S̲tochastic S̲imulation A̲lgorithm For Effective Spreading Dynamics On T̲ime-Evolving A̲daptive N̲etworX̲ (SSATAN-X)
  12. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
  13. Brain connectivity inversely scales with developmental temperature in Drosophila
  14. Stochastic Simulation Algorithm for effective spreading dynamics on Time-evolving Adaptive NetworX (SSATAN-X)
  15. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  16. Inferring gene regulatory networks from single-cell RNA-seq temporal snapshot data requires higher-order moments
  17. Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany
  18. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
  19. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
  20. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data
  21. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  22. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020
  23. Variable brain wiring through scalable and relative synapse formation in Drosophila
  24. ITN—VIROINF: Understanding (Harmful) Virus-Host Interactions by Linking Virology and Bioinformatics
  25. On the Sufficient Condition for Solving the Gap-Filling Problem Using Deep Convolutional Neural Networks
  26. COVIDStrategyCalculator: A standalone software to assess testing- and quarantine strategies for incoming travelers, contact person management and de-isolation
  27. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research
  28. Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
  29. Local c-di-GMP Signaling in the Control of Synthesis of the E. coli Biofilm Exopolysaccharide pEtN-Cellulose
  30. Autophagy-dependent filopodial kinetics restrict synaptic partner choice during Drosophila brain wiring
  31. Serial Synapse Formation through Filopodial Competition for Synaptic Seeding Factors
  32. SLCV–a supervised learning—computer vision combined strategy for automated muscle fibre detection in cross-sectional images
  33. Discerning the spatio-temporal disease patterns of surgically induced OA mouse models
  34. Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany
  35. The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis
  36. Analysis of long non-coding RNA and mRNA expression in bovine macrophages brings up novel aspects of Mycobacterium avium subspecies paratuberculosis infections
  37. Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis
  38. Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes
  39. In cell mutational interference mapping experiment (in cell MIME) identifies the 5′ polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging
  40. Statistical Analysis of the First Passage Path Ensemble of Jump Processes
  41. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
  42. In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements
  43. Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses
  44. Top-down and bottom-up models for nucleoside reverse transcriptase inhibitors against HIV-1
  45. MIMEAnTo: profiling functional RNA in mutational interference mapping experiments
  46. Systems-pharmacology modelling pipeline for PrEP against HIV-1
  47. Coupling cellular phenotype and mechanics to understand extracellular matrix formation and homeostasis in osteoarthritis * *financial support through BMBF project OVERLOAD-PrevOp, grant number 01EC1408H is acknowledged.
  48. Mutational interference mapping experiment (MIME) for studying RNA structure and function
  49. Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Escherichia coli
  50. Optimal Treatment Strategies in the Context of ‘Treatment for Prevention’ against HIV-1 in Resource-Poor Settings
  51. Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
  52. Assessment of Ambiguous Base Calls in HIV-1 pol Population Sequences as a Biomarker for Identification of Recent Infections in HIV-1 Incidence Studies
  53. Awareness and Utilization of Reporting Pathways for Adverse Events Following Immunization: Online Survey Among Pediatricians in Russia and Germany
  54. 'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays
  55. Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care
  56. Markov control processes with rare state observation: theory and application to treatment scheduling in HIV–1
  57. Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir
  58. In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis
  59. Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis
  60. Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses
  61. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
  62. HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection
  63. Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes
  64. HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs
  65. Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV
  66. Pharmacokinetic–pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine
  67. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution
  68. Software Supported Modelling in Pharmacokinetics
  69. Update on Antiviral DNA Vaccine Research (2000–2003)